JAFKX — Health Sciences Trust
Data updated: 2026-08-27
JAFKX — Health Sciences Trust. United States Large Cap Blend / Core Health Care Equity · $251.29M AUM. Holdings, fees, performance and SEC filings.
JAFKX Fund Overview
JAFKX — Health Sciences Trust is a US mutual fund managed by John Hancock Variable Insurance Trust, categorised as United States Large Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: John Hancock Variable Insurance Trust
- Category: United States Large Cap Blend / Core Health Care Equity
- Assets under management: $251.29M
- 1-year return: 31.9%
- Ticker: JAFKX
- SEC CIK: 0000756913
- SEC series ID: S000008239
- Share class ID: C000022444
JAFKX Holdings
Top 10 holdings of Health Sciences Trust by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly and Company | 14.30% |
| Johnson and Johnson | 6.33% |
| UnitedHealth Group Incorporated | 5.95% |
| AbbVie Inc. | 5.28% |
| Merck and Co. Inc. | 4.21% |
| Gilead Sciences Inc. | 2.95% |
| Thermo Fisher Scientific Inc. | 2.67% |
| Vertex Pharmaceuticals Incorporated | 2.38% |
| Bristol-Myers Squibb Company | 2.22% |
| Abbott Laboratories | 2.00% |
JAFKX Portfolio Allocation
Asset-class allocation of Health Sciences Trust by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.0% |
| Cash & Equivalents | 0.9% |
| Fixed Income | 0.1% |
JAFKX Performance
Total returns for JAFKX (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 7.2% |
| 1 year | 31.9% |
| 3 years (annualised) | 10.0% |
| 5 years (annualised) | 3.7% |
JAFKX Risk Information
Risk metrics for JAFKX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.5%
JAFKX Costs and Fees
JAFKX costs about $124 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.24%
- Gross expense ratio: 1.25%
- Portfolio turnover: 68%
- Brokerage commissions: 3.19 bps of average net assets (SEC N-CEN)
JAFKX Cashflows
Over the 12 months to 2026-06, Health Sciences Trust had net inflows of $5.65M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | −$479.76K |
| 2026-05 | −$2.57M |
| 2026-04 | −$4.72M |
| 2026-03 | −$2.89M |
| 2026-02 | −$959.99K |
| 2026-01 | $122.73K |
JAFKX Debt Constituents
Largest debt holdings of Health Sciences Trust by percentage of net assets, from the latest SEC N-PORT filing.
| Debt holding | % of net assets |
|---|---|
| Immunocore Holdings plc | 0.10% |
JAFKX Prospectus and SEC Filings
Official Health Sciences Trust filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-04-15
- Prospectus (485BPOS) — filed 2025-04-16
- Prospectus supplement (497) — filed 2024-12-12
- Portfolio holdings (N-PORT) — filed 2026-08-27
- Portfolio holdings (N-PORT) — filed 2026-05-29
- Portfolio holdings (N-PORT) — filed 2026-02-27
- Annual census (N-CEN) — filed 2026-03-11
- Annual census (N-CEN) — filed 2025-03-11
Related Funds
Other United States Large Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.